Bevacizumab induces regression of vestibular schwannomas in patients with neurofibromatosis type 2
Victor-Felix Mautner, Rosa Nguyen, Hannes Kutta, Carsten Fuensterer, Carsten Bokemeyer, Christian Hagel, Reinhard E Friedrich, Jens Panse, Victor-Felix Mautner, Rosa Nguyen, Hannes Kutta, Carsten Fuensterer, Carsten Bokemeyer, Christian Hagel, Reinhard E Friedrich, Jens Panse
Abstract
Bilateral vestibular schwannomas are the hallmark of neurofibromatosis type 2 (NF2), and these tumors impair hearing and frequently lead to deafness. Neurosurgical intervention, the only established treatment, often damages the vestibular nerve. We report 2 cases in which treatment with bevacizumab (for 3 months in one case and 6 months in the other) induced regression of progressive vestibular schwannomas by more than 40% and substantially improved hearing in the patient treated for 6 months. Bevacizumab therapy may thus provide an effective treatment for progressive vestibular schwannomas in patients with NF2.
Figures
Source: PubMed